https://doi.org/10.55788/612efd15
The single-centre, randomised, open-label EASY-HF trial (NCT06278792) tested the hypothesis that a nurse-led diuretic titration algorithm, informed by a point-of-care urine sodium device, could achieve greater natriuresis than physician-led standard-of-care [1]. Dr Evelyne Meekers (Hospital Oost-Limburg, Belgium) and colleagues wanted to find a way to implement the demanding protocol of natriuresis-guided diuretic therapy in patients with acute HF, which has recently been shown to improve decongestion and clinical outcomes [2].
EASY-HF enrolled 60 participants with HF and signs of congestion and volume overload, with NT-proBNP >500 ng/L (>800 ng/L in case of atrial fibrillation). Participants were randomised to standard-of-care diuretic management at the treating physician's discretion, or to a nurse-led natriuresis-guided protocol. A POC sensor (the UNa sensor) was used to measure the urinary sodium content. The primary endpoint was total natriuresis after 48 hours.
Natriuresis after 48 hours was significantly higher in the nurse-led group (820.0±279.0) than in the standard-of-care group (657.4±272.7), with an absolute difference of 163 (P=0.027). Dr Meekers observed that the largest benefit was achieved on the second day of treatment. She explained that the greater natriuresis in the nurse-led group was due to more frequent per-protocol changes in the dosage and higher dosing. Diuresis after 48 hours was also significantly higher in the nurse-led group: 7.3±2.4 L versus 6.0±1.9 L, with an absolute difference of 1.3 L (P=0.019). The nurses considered both the UNa sensor and the protocol easy to use. There was no significant difference in the incidence of hypotension, hypokalaemia, or renal dysfunction.
Dr Meekers noted that the POC UNa sensor provides a readily available bedside urinary sodium analysis, enabling the nurse to adjust diuretics rapidly. “The protocol and the POC UNa sensor were considered easily usable and adaptable, and were preferred to 24-hour urgent care in daily clinical practice by the nursing team, giving them tools for self-empowerment.” “The combination of a standardised protocol and the POC UNa sensor allows individualised diuretic titration during the first 48 hours in patients with acute decompensated HF) without the interference of a physician,” concluded Dr Meekers.
- Meekers E, et al. Readily available urinary sodium analysis in patients with acute decompensated heart failure. Late breaking clinical trials: medical therapy, Heart Failure 2024, 11–14 May, Lisbon, Portugal.
- Ter Maaten JM, et al. Nat Med. 2023;29:2625–32.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« Intravenous iron deficiency treatment improves exercise capacity in patients with HFpEF Next Article
SGLT2 inhibition: Major and early impact on heart failure hospitalisation risk »
« Intravenous iron deficiency treatment improves exercise capacity in patients with HFpEF Next Article
SGLT2 inhibition: Major and early impact on heart failure hospitalisation risk »
Table of Contents: HFA 2024
Featured articles
Meet the Trialist: Innovating cardiac monitoring with MONITOR-HF
Trials: Pharmacology
Effects of semaglutide on MACE irrespective of HF status
SEQUOIA-HCM: Aficamten demonstrates clinical efficacy in obstructive HCM
ARIES-HM3 trial: Subgroup analysis in patients with prior need for aspirin
Three diuretic regimens compared in the DEA-HF study
Adding a mineralocorticoid receptor modulator in heart failure with CKD
SGLT2 Inhibitors
Empagliflozin did not reduce mortality for HF after MI regardless of T2D status
SGLT2 inhibitors decrease atrial fibrillation risk in patients with HFrEF
SGLT2 inhibition: Major and early impact on heart failure hospitalisation risk
Trials: Other
Individualised diuretic titration in acute HF without a physician
Intravenous iron deficiency treatment improves exercise capacity in patients with HFpEF
CD34+ stem cells promote reverse cardiac remodelling after acute MI
Registries
Sex-specific outcomes and resource utilisation after HF hospitalisation
Application of guideline-directed medical therapy in patients with HFrEF in the Netherlands
Devices
PAP-guided management system appears safe in patients with HF
Delivery of CRT guided by non-invasive anatomy assessment
RELIEVE-ing HFrEF with interatrial shunting
Miscellaneous
Algorithm-based remote patient monitoring was associated with lower mortality in a retrospective cohort study
High mortality and morbidity in suspected de novo HF in outpatient care
Bio-ADM as a marker for congestion in patients hospitalised for acute HF
Hypertonic saline not effective in ambulatory patients with heart failure?
No effect of low-dose carperitide on mortality or hospitalisation in acute HF
Related Articles
June 15, 2022
Sotagliflozin SCORED MACE benefit
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com